Mesothelioma Treatment Comparison 2026: 3 Options That Change Your Odds

The 2025 ASCO guideline now recognizes three distinct first-line treatment regimens for mesothelioma — a fundamental shift from the single chemotherapy standard that dominated for two decades. Five-year data from CheckMate 743, published in the Journal of Clinical Oncology in February 2026, confirmed that immunotherapy more than doubles long-term survival: 14% of patients treated with nivolumab plus ipilimumab were alive at five years, compared to just 6% on chemotherapy. For patients and families evaluating options, this guide compares surgery, chemotherapy, and immunotherapy using the latest outcome data from the ASCO 2025 guideline update, FDA-approved protocols, and recent trial results.

What Are the Key Facts About Mesothelioma Treatment in 2026?

• Three ASCO-approved first-line regimens exist as of 2025 — a major shift from the prior single-standard era of platinum-pemetrexed chemotherapy
• Immunotherapy doubles 5-year survival: 14% with nivolumab plus ipilimumab versus 6% with chemotherapy per CheckMate 743's February 2026 data
• Non-epithelioid patients benefit most from immunotherapy: 12% versus 1% five-year survival in CheckMate 743, compared to 14% versus 8% for epithelioid disease
• Pembrolizumab plus chemotherapy received FDA approval on September 17, 2024, based on KEYNOTE-483 data showing a 25% three-year survival rate and 52% objective response rate
• Surgery is NOT routine — the 2025 ASCO guideline restricts it to early-stage epithelioid tumors (T1-3N0) treated at experienced mesothelioma centers
• The MARS2 phase III trial (2024) found surgery plus chemotherapy resulted in worse outcomes than chemotherapy alone in unselected patients — reinforcing the need for careful case selection
• Lung-sparing pleurectomy/decortication (P/D) is preferred over the more radical extrapleural pneumonectomy (EPP) when surgery is appropriate — a 7-month median OS advantage with 0–4% vs. 4–15% 30-day mortality
• Chemotherapy alone is no longer recommended for non-epithelioid mesothelioma by ASCO unless immunotherapy is contraindicated
• All mesothelioma patients should now be offered germline BAP1 genetic testing per the 2025 ASCO guideline — a high-evidence, strong recommendation
• ADI-PEG 20 (pegargiminase), a first-of-its-kind metabolic therapy for non-epithelioid mesothelioma, has a Biologics License Application under FDA review with a decision anticipated by late 2026

What Are the 3 Standard Treatment Options for Mesothelioma in 2026?

Mesothelioma treatment is no longer a one-size-fits-all decision. For the first time, the 2025 ASCO guideline officially codifies three separate systemic regimens as first-line standards, each with different evidence bases and appropriate patient populations.

Option 1: Dual Checkpoint Immunotherapy — Nivolumab Plus Ipilimumab

This combination, which blocks two distinct immune checkpoints (PD-1 and CTLA-4 simultaneously), emerged from the CheckMate 743 phase III trial as the most robust option for long-term survival. The five-year JCO data showed 14% overall survival at five years — more than double the 6% seen with chemotherapy. Approximately 17% of immunotherapy patients had ongoing tumor responses at five years, compared to 0% in the chemotherapy arm. ASCO recommends this as the preferred first-line option for all patients, particularly those with non-epithelioid histology.

Option 2: Pembrolizumab Plus Platinum-Pemetrexed Chemotherapy

The FDA approved this combination on September 17, 2024, based on KEYNOTE-483 results: median overall survival of 17.3 months versus 16.1 months for chemotherapy alone, with a 25% three-year survival rate versus 17% for chemotherapy. The response rate was notably higher with pembrolizumab plus chemotherapy (52% vs. 29%). This option is appropriate for both epithelioid and non-epithelioid disease and represents the first FDA approval of a new mesothelioma first-line regimen in years.

Option 3: Platinum-Pemetrexed Chemotherapy With or Without Bevacizumab

Traditional platinum-pemetrexed chemotherapy (cisplatin or carboplatin plus pemetrexed) remains a first-line option primarily for epithelioid patients where immunotherapy may be contraindicated. The addition of bevacizumab — an anti-VEGF antibody — can improve outcomes in eligible epithelioid patients. However, chemotherapy alone is now explicitly not recommended for non-epithelioid mesothelioma by ASCO unless immunotherapy cannot be used.

> "The days of offering every mesothelioma patient the same chemotherapy regimen are behind us. Cell type — epithelioid versus non-epithelioid — and performance status now drive very different treatment pathways, and patients who get the right match to their tumor biology have meaningfully better outcomes." > — David Foster, 18+ Years Mesothelioma Advocacy | 20 Years Pharmaceutical Industry | Host of MESO Podcast

How Does Surgery Compare to Chemotherapy for Mesothelioma Outcomes?

Surgery for mesothelioma is one of the most debated areas in oncology — and for good reason. The evidence is nuanced, center-dependent, and deeply tied to patient selection.

The Two Surgical Approaches

Two procedures have historically competed for use in eligible patients. Pleurectomy/Decortication (P/D) is a lung-sparing operation that removes the pleural lining and tumor deposits while preserving the lung. Extrapleural Pneumonectomy (EPP) is a more radical resection that removes the entire lung along with the pleura, pericardium, and diaphragm.

A 2025 systematic review and meta-analysis of 24 studies found P/D associated with a statistically significant 7.01-month improvement in median overall survival compared to EPP (95% CI: 1.15–12.86; p = 0.018), alongside dramatically lower 30-day mortality: 0–4% for P/D versus 4–15% for EPP. A 2026 Mount Sinai study of 71 carefully selected P/D patients reported 0% 30-day mortality and only 4.2% 90-day mortality — far better than the 9% 90-day mortality reported in MARS2.

The MARS2 Controversy

The MARS2 phase III trial (2024) randomized patients to extended P/D plus chemotherapy versus chemotherapy alone. The result was controversial: the surgery arm had worse survival at two years (19.3 months vs. 24.8 months; HR 1.28 for death, p = 0.032). High-volume centers strongly contested this finding, arguing that MARS2 enrolled unselected patients who should not have received surgery. The 2025 ASCO guideline took a cautious middle ground: surgery may be offered to highly selected patients with clinical early-stage (T1-3N0) epithelioid tumors, but should not be routinely offered based solely on anatomic resectability.

> "Surgery in mesothelioma is most valuable when the patient is carefully selected and the procedure is performed at a center that does enough of these operations to maintain genuine expertise. Volume matters enormously — 90-day mortality at a high-volume center can be four times lower than at an inexperienced one." > — David Foster, 18+ Years Mesothelioma Advocacy | 20 Years Pharmaceutical Industry | Host of MESO Podcast

For a detailed comparison of surgical approaches, the P/D versus EPP comparison guide at Mesothelioma.net covers the key outcome differences. Finding the right specialized mesothelioma treatment center — one with genuine surgical volume — is equally important.

Why Has Immunotherapy Become the Standard of Care for Most Patients?

The pivotal shift to immunotherapy as the preferred first-line option stems from a clear survival advantage — particularly at the five-year mark — that chemotherapy has never achieved in mesothelioma.

CheckMate 743: The Defining Trial

CheckMate 743 randomized 605 previously untreated patients to nivolumab plus ipilimumab versus platinum-pemetrexed chemotherapy. The five-year follow-up data, published in the Journal of Clinical Oncology in February 2026, represents the longest reported follow-up for any first-line regimen in pleural mesothelioma:

Outcome	Immunotherapy	Chemotherapy
Median overall survival	18.1 months	14.1 months
5-year overall survival	14%	6%
5-year progression-free survival	8%	0%
Ongoing tumor responses at 5 years	17%	0%
Non-epithelioid 5-year OS	12%	1%

For non-epithelioid disease specifically, immunotherapy was transformative: the hazard ratio for death was 0.48, meaning patients on immunotherapy had roughly half the risk of death compared to those on chemotherapy. No new safety signals were observed at five years.

Why Chemotherapy Falls Short Long-Term

Chemotherapy produces initial tumor responses in many patients — the objective response rate in CheckMate 743's chemotherapy arm was 44%. But responses are short-lived. By five years, not a single chemotherapy-arm patient maintained an ongoing tumor response, versus 17% of immunotherapy patients. The durability of checkpoint inhibitor responses — driven by immune memory — is what distinguishes immunotherapy from chemotherapy in this disease.

> "What the CheckMate 743 five-year data tells us is that immunotherapy doesn't just extend the median — it creates a population of long-term survivors that chemotherapy cannot produce. That 17% of patients still responding at five years represents something genuinely new in this disease." > — David Foster, 18+ Years Mesothelioma Advocacy | 20 Years Pharmaceutical Industry | Host of MESO Podcast

Patients who want to compare their immunotherapy options against current enrolling studies can use the mesothelioma clinical trials directory at WikiMesothelioma. Our immunotherapy overview article covers nivolumab and pembrolizumab mechanisms in detail, and our guide to the recently FDA-approved subcutaneous Opdivo formulation explains the faster 5-minute administration option.

What Does the 2025 ASCO Guideline Recommend for Each Patient Type?

The 2025 ASCO update provides histology-specific recommendations — a significant advance over prior guidelines that treated all mesothelioma patients as a single group. Understanding where you fit is essential.

First-Line Systemic Therapy by Cell Type

Histology	Preferred Option	Alternative
Non-epithelioid (sarcomatoid/biphasic)	Nivolumab + ipilimumab	Pembrolizumab + chemotherapy
Epithelioid	Nivolumab + ipilimumab OR pembrolizumab + chemo	Pemetrexed + platinum ± bevacizumab
Any histology (immunotherapy contraindicated)	Pemetrexed + platinum	Pegargiminase + chemo (non-epithelioid, conditional)

PD-L1 status, TMB, and MSI testing should not drive treatment selection — the guideline is explicit on this point. Cell type and performance status are what matter. For surgical candidates, the guideline restricts surgery to highly selected T1-3N0 epithelioid patients at experienced centers, with P/D preferred over EPP.

The guideline also made a naming change: the disease should now simply be called "mesothelioma" — the word "malignant" has been dropped as redundant.

For second-line therapy, patients previously treated with chemotherapy can receive double or single-agent immunotherapy. Patients who progressed after immunotherapy may receive chemotherapy. Understanding your mesothelioma stage and how it affects treatment eligibility is a critical first step before comparing options.

What Emerging Treatments Could Change Outcomes Beyond 2026?

Three pipeline therapies could meaningfully expand the treatment toolkit within the next one to two years.

ADI-PEG 20 (Pegargiminase) — Metabolic Therapy

Approximately 50% of mesotheliomas lack expression of argininosuccinate synthetase 1 (ASS1), making tumor cells dependent on circulating arginine. ADI-PEG 20 depletes that arginine, starving susceptible cancer cells. In the ATOMIC-Meso phase III trial, pegargiminase plus chemotherapy reduced the risk of disease progression by 34% (HR 0.66) compared to chemotherapy alone in non-epithelioid patients, and some patients achieved survival beyond three years — exceptional for sarcomatoid disease. A Biologics License Application is currently under FDA review; if approved, it would become the first metabolic therapy for mesothelioma. The 2025 ASCO guideline already includes a conditional recommendation for pegargiminase in non-epithelioid patients who cannot receive immunotherapy.

Mesothelin-Targeted CAR-T Cell Therapy

Memorial Sloan Kettering's phase I trial of intrapleurally administered mesothelin-targeted CAR-T cells combined with pembrolizumab achieved a 72% objective response rate in 11 mesothelioma patients, including two durable complete metabolic responses. The approach targets mesothelin, a protein overexpressed in over 90% of mesotheliomas. CAR-T cells persisted in the bloodstream of 13 of 21 patients through the 38-week evaluation period, with persistence correlating with tumor regression. A phase I dose-escalation trial (NCT04577326) is currently enrolling at MSK.

Perioperative Immunotherapy Before Surgery

A Johns Hopkins phase II trial presented at WCLC 2025 tested neoadjuvant nivolumab plus ipilimumab before surgery in resectable mesothelioma. Patients who received the combination before surgery had a median overall survival of 28.6 months — substantially better than the 19.3-month OS in patients who received nivolumab alone. Circulating tumor DNA (ctDNA) analyses from the trial accurately predicted surgical outcomes, pointing toward a future where liquid biopsy guides treatment decisions before the patient enters the operating room.

> "The perioperative immunotherapy data from Johns Hopkins is particularly exciting because it suggests we might be able to identify before surgery — using a blood test — which patients will benefit most from going to the operating room. That's personalized medicine in action." > — David Foster, 18+ Years Mesothelioma Advocacy | 20 Years Pharmaceutical Industry | Host of MESO Podcast

Understanding the terminology used in these trials is simplified by the mesothelioma medical terms glossary at WikiMesothelioma, which covers over 63 key diagnostic and treatment terms. For patients interested in clinical trial eligibility, our 2026 clinical trials guide covers active enrollment opportunities by treatment category.

Frequently Asked Questions?

---

References

1. Kindler HL, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025. DOI: 10.1200/JCO-24-02425.
2. Baas P, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. Journal of Clinical Oncology. 2026. DOI: 10.1200/JCO-25-01328.
3. U.S. Food and Drug Administration. FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced Malignant Pleural Mesothelioma. September 17, 2024. fda.gov
4. National Cancer Institute. Mesothelioma Treatment PDQ. 2025. cancer.gov
5. Merck. KEYNOTE-483: Pembrolizumab Plus Chemotherapy Significantly Improved Overall Survival vs. Chemotherapy Alone. 2024. merck.com
6. Bueno R, et al. Pleurectomy/Decortication vs. Extrapleural Pneumonectomy: Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2025. DOI: 10.3390/jcm14175964.
7. Lim E, et al. MARS2: Extended Pleurectomy Decortication and Chemotherapy versus Chemotherapy Alone for Resectable Mesothelioma. The Lancet. 2024. PubMed 38740044
8. Szlosarek PW, et al. ATOMIC-Meso: Pegargiminase Plus First-Line Chemotherapy in Non-Epithelioid Pleural Mesothelioma. JAMA. 2024. PMC10870227.
9. Novocure. FDA Approves NovoTTF-100L System for Malignant Pleural Mesothelioma. May 2019. novocure.com
10. ASCO Post. Pleurectomy/Decortication Safe in Select Patients With Pleural Mesothelioma. February 2026. ascopost.com
11. eCancer Medical Science. WCLC 2025: First-Ever Clinical Trial Demonstrates Safety of Perioperative Immunotherapy for Operable Mesothelioma. 2025. ecancer.org
12. Kindler HL, et al. ASCO 2025 Treatment Guidelines Clinical Insights: Three First-Line Regimens. JCO Oncology Practice. 2025. DOI: 10.1200/OP-25-00035.
13. Mesothelioma.net. Pleurectomy/Decortication vs. Extrapleural Pneumonectomy. 2025. mesothelioma.net
14. WikiMesothelioma. Mesothelioma Treatment Centers. wikimesothelioma.com
15. WikiMesothelioma. Mesothelioma Clinical Trials. wikimesothelioma.com
16. WikiMesothelioma. Medical Terms Glossary. wikimesothelioma.com